Rituximab treatment of idiopathic membranous nephropathy

Kidney International

Volumn 73, Issue 1, 2008, Pages 117-125

  Fervenza, F C ^a   Cosio, F G ^a   Erickson, S B ^a   Specks, U ^a   Herzenberg, A M ^b   Dillon, J J ^a   Leung, N ^a   Cohen, I M ^a   Wochos, D N ^a   Bergstralh, E ^a   Hladunewich, M ^b   Cattran, D C ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Membranous nephropathy; Nephrotic syndrome; Pharmacodynamics, HACA; Pharmacokinetics; Rituximab

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; CYCLOSPORIN A; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENHYDRAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISONE; RITUXIMAB;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ERUPTION; EDEMA; ENZYME INHIBITION; FATIGUE; FEMALE; FOLLOW UP; HAIR LOSS; HERPES ZOSTER; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FIBROSIS; LARYNX DISORDER; LUNG ADENOCARCINOMA; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MYALGIA; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; REMISSION; RIGOR; SERUM SICKNESS; SIDE EFFECT; SORE THROAT; VIRUS REACTIVATION;

EID: 37248999499     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002628     Document Type: Article

References (30)

1. Cattran DC. Membranous nephropathy: quo vadis? [comment]. Kidney Int 2002; 61: 349-350.
2. Ruggenenti P, Chiurchiu C, Brusegan V et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003; 14: 1851-1857.
3. Kerjaschki D, Neale TJ. Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol 1996; 7: 2518-2526.
4. Ponticelli C, Zucchelli P, Passerini P et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995; 48: 1600-1604.
5. Cupps TR, Edgar LC, Fauci AS. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982; 128: 2453-2457.
6. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion [see comment]. Ann Rheum Dis 2002; 61: 883-888.
7. Anolik JH, Campbell D, Felgar RE et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48: 455-459.
8. Silverman GJ. Anti-CD20 therapy and autoimmune disease: therapeutic opportunities and evolving insights. Front Biosci 2007; 12: 2194-2206.
9. Remuzzi G, Chiurchiu C, Abbate M et al. Rituximab for idiopathic membranous nephropathy. Lancet 2002; 360: 923-924.
10. Keogh KA, Ytterberg SR, Fervenza FC et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173: 180-187.
11. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589.
12. Cohen CD, Calvaresi N, Armelloni S et al. CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol 2005; 18: 328-333.
13. Ruggenenti P, Chiurchiu C, Abbate M et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 2006; 1: 738-748.
14. Cattran DC. Idiopathic membranous glomerulonephritis. Kidney Int 2001; 59: 1983-1994.
15. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int Suppl 1994; 45: S145-S149.
16. Apperloo AJ, de Zeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int Suppl 1994; 45: S174-S178.
17. Keane WF, Brenner BM, de Zeeuw D, Investigators RS et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003; 63: 1499-1507.
18. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
19. Cattran D. Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol 2005; 16: 1188-1194.
20. Pei Y, Cattran D, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 1992; 42: 960-966.
21. Piro LD, White CA, Grillo-Lopez AJ et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma [see comment]. Ann Oncol 1999; 10: 655-661.
22. Zaja F, Iacona I, Masolini P et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia [see comment] [published erratum appears in Haematologica 2002; 87: 336]. Haematologica 2002; 87: 189-195.
23. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
24. Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135-3143.
25. Gonzalez-Stawinski GV, Yu PB, Love SD et al. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Clin Immunol 2001; 98: 175-179.
26. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581.
27. Troyanov S, Roasio L, Pandes M et al. Renal pathology in idiopathic membranous nephropathy: a new perspective. Kidney Int 2006; 69: 1641-1648.
28. Salama AD, Pusey CD. Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2006; 2: 221-230.
29. Hunter MG, Hurwitz S, Bellamy CO, Duffield JS. Quantitative morphometry of lupus nephritis: the significance of collagen, tubular space, and inflammatory infiltrate. Kidney Int 2005; 67: 94-102.
30. Cattran DC, Appel GB, Hebert LA, North America Nephrotic Syndrome Study Group et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001; 59: 1484-1490.